Neoprol Overview
- Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Seed
- Investors
-
1
Neoprol General Information
Description
Developer of medical formulations designed to focus on the preparation of anesthesia drugs. The company's medical formulations offer the development of propofol product that is used for intravenous induction and maintenance of anesthesia, enabling patients to avoid any side effects of anesthesia.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- Givat Ram
- Jerusalem
- Israel
Neoprol Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 01-Mar-2019 | Completed | Generating Revenue |
Neoprol Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Nissim Garti | Founder & Chief Executive Officer |
Neoprol Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Yatindra Joshi | Neoprol | Chairman | 000 0000 |
Neoprol Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Integra Holdings | Venture Capital | Minority | 000 0000 | 000000 0 |